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(57) ABSTRACT 
The present invention provides a vascular conduit device 
including a deformable flange and complementary securing 
ring in cooperation for securing the device within an aperture 
defined in a tissue wall. The present invention further pro-
vides a system for implanting such a vascular conduit device 
in a tissue wall. More specifically, the present invention pro-
vides a system including a coring device for defining an 
aperture in a tissue wall (such as a ventricle and/or a blood 
vessel) and securely implanting a vascular conduit device 
therein so as to provide fluid communication between a first 
and second surface of the tissue wall via the vascular conduit 
device. 
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VASCULAR CONDUIT DEVICE AND SYSTEM 
FOR IMPLANTING 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of copending 
U.S. patent application Ser. No. 10/915,691, filed on Aug. 11, 
2004, now abandoned, which is hereby incorporated herein in 
its entirety by reference. 
FIELD OF INVENTION 
2 
until the cuff comes to rest: on the apex. The sutures are tied 
off, and additional sutures may be added. Either before or 
after this procedure, the opposite end of the connector is 
attached to a valved conduit which terminates at the aorta. 
The current techniques and technology available to per-
formAAC insertion were originally designed to be performed 
on-pump; either with an arrested or fibrillating heart. While 
off-pump cases have been described, they can be technically 
difficult due to the shortcomings of presently available vas-
10 cular conduits and systems for installing such conduits. For 
example, because existing conduits require the use of sutures 
to reliably secure the connector in place, it is often difficult for 
surgeons or other clinicians to insert such sutures reliably in 
active cardiac and/or vascular tissue. This invention relates to devices and methods for creating 
and maintaining a fluid conduit in a tissue wall. For example, 15 
some embodiments of the present invention may provide an 
alternative conduit between the left ventricle and the aorta to 
SUMMARY OF THE INVENTION 
create a double-outlet left ventricle. 
BACKGROUND OF THE INVENTION 
Construction of an alternative conduit between the left 
ventricle and the aorta (an apicoaortic conduit, or AAC) to 
create a double-outlet left ventricle (LV) has been success-
fully employed to treat a variety of complex congenital LV 
outflow obstruction (fibrous tunnel obstruction, aortic annu-
lar hypoplasia, tubular hypoplasia of the ascending aorta, and 
patients with diffuse septa! thickening, severe LV hypertro-
phy and a small LV cavity) as well as adult-onset aortic 
stenosis in patients with complicating preoperative condi-
tions (previous failed annular augmentation procedures, pre-
vious infection, previous CABG with patent anterior internal 
mammary artery grafts, and a porcelain ascending aorta). 
However, the AAC insertion procedure has been poorly 
accepted, primarily because of early valve failures using first-
generation bioprostheses as well as the success of direct 
LVOTO repair and aortic valve replacement. In the United 
States, despite an aging population, the unadjusted mortality 
for isolated aortic valve operations in 2001 remained under 
4%. Further, the AAC insertion operation, with or without 
cardiopulmonary bypass, has not been as technically straight-
forward as direct aortic valve replacement. For most sur-
geons, AAC insertion is not a familiar operation and is of 
historical interest only. 
Nonetheless, several studies have demonstrated that AAC 
insertion successfully lessens the LY-aortic pressure gradient, 
preserves or improves ventricular function and maintains nor-
mally distributed blood flow through the systemic and coro-
nary circulation. While there have been several techniques 
described, the most commonly employed method is the lat-
eral thoracotomy approach with placement of the AAC to the 
descending aorta. Other techniques include a median stemo-
tomy approach with insertion of the distal limb of the AAC to 
the ascending aorta, to the transverse part of the aortic arch, or 
to the intra-abdominal supraceliac aorta. 
In general, the thoracic aorta and the left ventricle apex are 
exposed through a left lateral thoracotomy, and a needle is 
passed through the apex and into the left ventricle. While the 
connector is still spaced apart from the apex, the sutures that 
will fix the connector to the apex are threaded through a cuff 
on the connector and through the apex in a matching pattern. 
The cuff is set back from the end of the connector by 1-2 
centimeters to allow the end of the connector to extend 
through the heart muscle and into the left ventricle. Once the 
sutures are in place, a ventricular coring device is used to 
remove a core of ventricular muscle, and the pre-threaded 
sutures are then pulled to draw the connector into the opening 
This invention describes an improved system and method 
for the insertion of a vascular conduit (such as an AAC) that 
20 will significantly improve and simplify the in vivo insertion of 
a graft into the beating cardiac apex orothertissue walls (such 
as other areas of the heart including the anterior, lateral, 
posterior walls of the left or right ventricle, the left or right 
atrium, the aortic wall, ascending, transverse, or descending, 
25 or other blood vessel walls), such that vascular conduit inser-
tions (including AAC procedures) may be rendered far more 
attractive to clinicians. Because vascular conduits and sys-
tems of the present invention may be used to create alternate 
outflow tracts in "off-pump" procedures, the embodiments of 
30 the present invention may effectively reduce and/or negate the 
detrimental effects of both cardio-pulmonary by-pass (CPB) 
and global cardiac ischemia.Additionally, because some con-
duit embodiments of the present invention (for AAC proce-
dures, for example) may be inserted into a ventricular or atrial 
35 free wall or cardiac apex, the conduction system of the heart 
may be avoided, along with the native coronary arteries and 
grafts from previous surgical revascularization. In some 
embodiments of the present invention, wherein the system is 
used to implant anAAC, a small size valve (19 to 21 mm for 
40 typical adult body surface areas) is usually adequate; as the 
effective postoperative orifice is the sum of the native and 
prosthetic aortic valves. Further, the present invention pro-
vides vascular conduits that may be compatible with newer 
generation biologic valves, such that valved conduit failure is 
45 far less likely. 
In one embodiment, the present invention provides a sys-
tem for implanting a vascular conduit device (such as anAAC 
component). According to some embodiments, the system 
comprises a coring device for defining an aperture in a tissue 
50 wall (such as a cardiac free wall or apex and/or the aorta) 
having a first tissue surface and a second tissue surface. The 
coring device may define a lumen adapted to be capable of 
receiving a guide wire for directing the coring device to the 
first or second tissue surface, depending upon whether the 
55 approach is intra- or extra-vascular, respectively. The system 
may also comprise a conduit device for lining the aperture 
defined in the tissue wall and maintaining fluid communica-
tion between the first and second tissue surfaces of the tissue 
wall. The conduit device may be adapted to be capable of 
60 being advanced over the guide wire and/or the coring device 
so as to be guided to the aperture defined by the coring device. 
The conduit device may comprise, in some embodiments: a 
tube having proximal and distal ends, and inside and outside 
surfaces; a flexible flange disposed at or near the distal end, 
65 wherein the flexible flange is adapted to be capable of oper-
ably engaging the first tissue surface; and a securing ring 
adapted to fit over the tube and adapted to be capable of 
US 9, 138,228 B2 
3 
operably engaging the second tissue surface and cooperating 
with the flexible flange so as to secure the conduit device 
within the aperture. 
According to some embodiments of the present invention, 
the system may also comprise a hemostatic device for selec-
tively deploying so as to temporarily occlude the aperture (so 
as to prevent the passage of blood through the aperture and 
into an adjacent body cavity, for example). The hemostatic 
device may also be adapted to be capable of being advanced 
over the guide wire and/or within the lumen of the coring 
device such that the hemostatic device may be accurately 
guided to the site of the newly-formed aperture created by the 
coring device. The hemostatic device may comprise at least 
one of an "umbrella" occlusion device, a dilation balloon, 
and/ or combinations of such devices. Furthermore, according 
4 
According to some embodiments of the present invention, 
the flexible flange may be soft and thin enough to bend back-
wards so that it can be pushed through the aperture defined in 
the tissue wall, but rigid enough to flex back to its original 
position and hold its shape once it emerges along a first tissue 
surface of the tissue wall. The tube of the vascular conduit 
device may then be drawn back so that the flexible flange 
presses against the first tissue surface of the tissue wall. The 
securing ring may then be deployed over the body of the 
10 connector and against the second tissue surface of the tissue 
wall. Various vascular conduit device embodiments are 
described herein to secure the position of the second ring 
against a surface of the tissue wall such that no sutures may be 
required. Such embodiments may include, but are not limited 
15 to: the ridge and pawl mechanism described above, a threaded 
surfaces disposed on the tube and an inner surface of the 
securing ring, a biasing device for biasing the securing ring 
toward the flange; and/or combinations of such securing 
to various system embodiments of the present invention, the 
coring device may comprise at least one of: a pulsed laser 
scalpel; a continuous wave laser scalpel; a mechanical coring 
device; a device employing ultrasonic energy (such as high-
frequency focused ultra-sound); and/or combinations of such 20 
coring devices. Some embodiments of the present invention 
may also provide a specialized delivery device for enclosing 
the conduit device and selectively implanting the conduit 
device within the aperture. The delivery device may be oper-
ably engaged with an outer surface of the coring device and 
may comprise one or more retracting arms for dilating the 
aperture prior to and/or simultaneously with the implantation 
devices. 
According to one embodiment for using the new system 
and/or vascular conduit device of the present invention, a 
needle is passed through a tissue wall (such as the wall of the 
cardiac apex) to provide access to the first tissue surface 
(defining the interior of the left ventricle, for example). A 
25 guide wire may then be inserted into the opening and, follow-
ing dilation of the opening, an occlusion device may be 
threaded over the wire and into a cavity defined by the tissue 
wall and deployed. A coring device may then be threaded 
in-line over the guide wire such that a core of tissue may be 
of the conduit device. 
Some additional system embodiments of the present inven-
tion may also comprise a guiding catheter defining a guiding 
lumen for receiving and directing the coring device and the 
conduit device to the tissue wall via an endovascular pathway. 
Thus, according to various system embodiments of the 
present invention, the system may be used to implant the 
conduit device via an endovascular pathway such that the 
conduit may be implanted from inside the left ventricle and/or 
inside another blood vessel. 
Other embodiments of the present invention provide a vas-
cular conduit device for lining an aperture defined in a tissue 
wall (such as the cardiac wall, apex and/or a blood vessel 
wall) and maintaining fluid communication between a first 
tissue surface and a second tissue surface of the tissue wall. 
According to some embodiments, the vascular conduit device 
may comprise a tube having proximal and distal ends, and 
inside and outside surfaces, wherein the outside surface of the 
tube defines a plurality of ridges. The vascular conduit device 
may further comprise a flexible flange disposed at or near the 
distal end for operably engaging the first tissue surface and a 
securing ring adapted to fit over the tube for operably engag-
ing the second tissue surface. The securing ring may also 
comprise at least one deformable pawl member for releasably 
engaging the plurality of ridges defined by the outer surface of 
the tube such that the securing ring cooperates with the flex-
ible flange so as to secure the vascular conduit device within 
the aperture. 
30 removed to form an aperture in the tissue wall. While the 
occlusion device maintains hemostasis, the coring device 
may be removed and the vascular conduit device of the 
present invention may be mounted on a dilator and introduced 
over the guide wire and occlusion device catheter. As the 
35 vascular conduit device is introduced into the aperture, the 
flexible flange retracts. Furthermore, as discussed above, as 
the vascular conduit device enters the aperture, it may dis-
place the occlusion device to allow the flange to resume its 
normal shape. As discussed above, the vascular conduit 
40 device may then be drawn tight against the first tissue wall 
such that the securing ring may be deployed over the body of 
the vascular conduit device to fit snugly against the second 
tissue surface. Once the connector is firmly in place, the 
occlusion device may be withdrawn and the vascular conduit 
45 device may be clamped shut while its free end is connected to 
a vascular graft or valved conduit that may terminate at 
another tissue wall (such as a blood vessel wall, for example). 
Use of this new vascular conduit device, system, and 
method will significantly improve the ease and safety of 
50 vascular conduit insertion (such as the implantation of AAC 
devices). As persons of ordinary skill would readily appreci-
ate, this method can also be, used in a minimally invasive, 
endoscopically assisted approach. 
55 BRIEF DESCRIPTION OF THE DRAWINGS 
According to some embodiments, the flexible flange and/or 
securing ring may define complementary concave and/or 
convex profiles so as to conform more completely to the first 
and second tissue surfaces. Furthermore, the flexible flange 
may comprise a frusto-conical assembly such that the flange 60 
may be more easily inserted into the aperture. According to 
various other embodiments of the present invention, the out-
side surface of the tube may comprise threading on at least a 
portion of the outside surface of the tube and corresponding 
threading on an inside diameter of the securing ring such that 65 
the securing ring may be secured with respect to the flange 
and the tissue wall held there between. 
The invention will be better understood by reference to the 
Detailed Description of the Invention when taken together 
with the attached drawings, wherein: 
FIG. 1 is a perspective view of a first embodiment of an LV 
apical connector according to the invention; 
FIG. 2 is a side view of the embodiment shown in FIG. 1; 
FIG. 3 is a perspective view oft second embodiment of an 
LV apical connector according to the invention; 
FIG. 4 is a side view of the embodiment shown in FIG. 3; 
FIG. 5 is aside view of a third embodiment of an LV apical 
connector according to the invention. 
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FIG. 6 is a perspective view of a vascular conduit device, 
including a tube, flexible flange, and securing ring, according 
to one embodiment of the present invention. 
FIG. 7 is a perspective view of a vascular conduit device, 
including a tube, flexible flange, and securing ring, according 
to one embodiment of the present invention, wherein the 
flexible flange and securing rings define convex and concave 
profiles, respectively. 
FIG. SA is a cross-sectional view of a tissue wall and 
aperture defined therein in relation to one system embodi-
ment of the present invention including a coring device for 
defining an aperture and a vascular conduit device for defin-
ing and maintaining the aperture. 
FIG. SB is a cross-sectional view of a tissue wall and 
aperture defined therein including a side view of a vascular 
conduit device, according to one embodiment of the present 
invention, implanted in the aperture. 
FIG. 9A is a cross-sectional side view of a system accord-
ing to one embodiment of the present invention including a 
delivery device for enclosing and selectively delivering the 
conduit device. 
FIG. 9B is a cross-sectional side view of a system accord-
ing to one embodiment of the present invention including a 
delivery device comprising a pair of retracting arms for dilat-
ing the aperture during implantation of the conduit device. 
FIG. 10 is a cross-sectional side view of an exemplary 
apico-aortic connection (AAC) constructed using some 
embodiments of the present invention. 
FIG. 11 is a side view of an exemplary embodiment of the 
conduit device of the present invention including a notch and 
pin arrangement for selectively engaging the conduit device 
with a coring device. 
FIG. 12 is a cross-sectional side view of an exemplary 
apico-aortic connection (AAC) inserted via endovascular 
methods using system embodiments of the present invention. 
DETAILED DESCRIPTION OF THE INVENTION 
The present inventions now will be described more fully 
hereinafter with reference to the accompanying drawings, in 
which some, but not all embodiments of the inventions are 
shown. Indeed, these inventions may be embodied in many 
different forms and should not be construed as limited to the 
embodiments set forth herein; rather, these embodiments are 
provided so that this disclosure will satisfy applicable legal 
requirements. Like numbers refer to like elements through-
out. The singular forms "a," "an," and "the" include plural 
referents unless the context clearly dictates otherwise. 
Although some embodiments of the invention described 
herein are directed to a vascular conduit device 100 and a 
system for implanting such a device to form an apico-aortic 
connector (AAC) between the cardiac apex and the aorta, it 
will be appreciated by one skilled in the art that the invention 
is not so limited. For example, aspects of the vascular conduit 
device 100 and systems of the present invention can also be 
used to establish and/or maintain conduits in a variety of 
tissue structures using minimally-invasive and/or invasive 
delivery techniques. Furthermore, while the embodiments of 
the invention described herein are directed to the thoraco-
scopic implantation of the vascular conduit device to form at 
least one vascular port for establishing an AAC, it should be 
understood that the system and/or vascular conduit device 
embodiments of the present invention may be used to estab-
lish valved and/or open conduits (including bypass conduits) 
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tract obstructions (LVOTO), peripheral arterial obstructions, 
small vessel obstructions, and/or other conditions. Further-
more, the vascular conduit device and system of the present 
invention may also be used to establish a port for inter-ven-
tricular repairs such as, for example, valve repair and/or 
replacement or ablation procedures. Thus, the vascular con-
duit device 100 described in further detail below may also 
comprise a threaded fluid-tight cap, and/or a cap having at 
least one pawl member (for engaging corresponding ridges 
10 defined on an outer surface of the vascular conduit device 
100) for selectively sealing the proximal end 7 of the vascular 
conduit device 100 such that the tube 1 may serve as a re-
usable port for repairing and/or treating diseased portions of 
the cardiac anatomy. Furthermore, the vascular conduit 
15 device 100 and system embodiments of the present invention 
may also be used to implant a conduit and/or port for left 
ventricular assist devices. 
Furthermore, (as shown generally in FIG. 12) some system 
embodiments of the present invention may also be used "from 
20 the inside out'', such that the coring device S30 and conduit 
device 100 may be passed from through an intravascular 
space (percutaneously). For example, in one possible 
embodiment, the system embodiments of the present inven-
tion may be used to establish an apico-aortic conduit (AAC) 
25 percutaneously (see FIG. 12). The system components may 
be introduced (via methods that will be appreciated by one 
skilled in the art) into the femoral vein, across the atrial 
septum, through the mitral valve and out the ventricular free 
wall. Therefore, the ventricular conduit device (see element 
30 lOOa, FIG. 12) would be placed from inside the vasculature 
(via a guiding catheter, for example). In similar fashion, the 
aortic conduit device (see element lOOb, FIG. 12) may be 
passed retrograde in the femoral artery (via guide wire and/or 
guiding catheter) or other blood vessel and implanted using 
35 the systems of the present invention from the luminal side of 
the aorta. The two connectors would then be joined with a 
valved conduit introduced from either end of the system (see 
FIG. 12). 
As showninFIGS.1 and2, the vascular conduit device 100 
40 according to one embodiment of the present invention 
includes tube (or conduit) 1 having an axis 3, distal end 5, a 
proximal end 7, an outer surface 9 and an inner surface 11. 
Distal end 5 is provided with a flange 13 extending, from 
outer surface 9 in a direction away from axis 3. Flange 13 may 
45 be integrally formed with tube 1, or it maybe formed sepa-
rately and permanently attached to distal end 5 of tube 1 by 
known means. Tube 1 should be sufficiently rigid to maintain 
its shape so as not to occlude the passage ofblood and/or other 
fluids therethrough during use (see generally, element S60, 
50 FIG. SB). Flange 13 may be sufficiently flexible to allow 
introduction of the distal end 5 of the vascular conduit device 
100 into an aperture SOO (see FIG. SA) having a diameter 
equal to or slightly less than the diameter of outer surface 9, 
but have sufficient stiffness and/or shape memory to flex back 
55 to its original position once it has passed through the aperture 
SOO (which may be defined in a tissue wall S50, as shown 
generally in FIGS. SA-SB). 
As shown generally in FIGS. SA-SB, the vascular conduit 
device 100 may maintain and/or provide a lining for an aper-
60 ture SOO defined in a tissue wall S50 so as to maintain fluid 
to augment native blood vessels in order to treat a variety of 65 
vascular conditions including, but not limited to: aortic val-
vular disease, congestive heart failure, left ventricle outflow 
communication S60 between a first tissue surface S53 and a 
second tissue surface S55 of the tissue wall S50. As described 
generally above, and as shown in FIGS. 6 and 7, the vascular 
conduit device 100 may comprise a tube 1 having proximal 7 
and distal 5 ends, and inside and outside surfaces, wherein the 
outside surface of the tube 1 defines a plurality of ridges 610. 
According to some embodiments, the vascular conduit device 
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100 may also comprise a flexible flange 13 disposed at or near 
the distal end 5 for operably engaging the first tissue surface 
S53 (see FIG. SB). As shown in FIGS. 6 and 7, the vascular 
conduit device 100 may also comprise a securing ring 17 
adapted to fit over the tube 1 and having a flange 630 for 
operably engaging the second tissue surface S55. The secur-
ing ring 17 may also comprise at least one deformable pawl 
member 620 for releasably engaging the plurality of ridges 
610 defined by the outer surface of the tube 1 such that the 
securing ring 17 cooperates with the flexible flange 13 so as to 
secure the vascular conduit device 100 within the aperture 
SOO. In one embodiment, the securing ring 17 comprises a 
flange 630 configured to engage the second tissue surface 
S55, and the deformable pawl member 620 extends axially 
along the axis 3 of the tube 1 at an opposite end of the flange. 
According to one aspect, the securing ring 17 has a wall 
thickness, and the deformable pawl member is defined by a 
pair of slots 632 formed through the wall thickness as shown 
in FIGS. 6 and 7. 
As shown generally in FIG. SB, once the vascular conduit 
device 100 is secured within the aperture SOO defined in the 
tissue wall S50, the vascular conduit device 100 may define a 
pathway for fluid communication (and/or a pathway for tho-
racoscopic instruments or other surgical tools) between a first 
tissue surface S53 and a second tissue surface S55. Further-
more, the proximal end 7 of the vascular conduit device 100 
may be configured to receive a number of different valved 
and/or open conduits for creating, for example, vascular 
bypasses or other alternate fluid pathways within a living 
organism. For example, according apico-aortic conduit 
embodiments of the present invention (see FIG. 10), a first 
vascular conduit device lOOa (shown generally in FIG. 6) 
may be implanted and/or secured in the apex S50a of the left 
ventricle, and a second vascular conduit device lOOb (shown 
generally in FIG. 7) may be implanted and/or secured within 
a wall S50b of the aorta. The two devices may then be con-
nected via a commercially-available valved conduit device 
1020 (including a one-way valve 1025) in order to create an 
alternative valved pathway for blood in order to augment a 
diminished flow of blood that may be passing through a 
diseased and/or damaged aortic valve. Thus, according to 
some embodiments, the proximal end 7 of the tube 1 defining 
the fluid pathway through the vascular conduit device 100 
may be formed so as to be compatible with one or more 
existing valved conduit devices 1020. Furthermore, accord-
ing to some embodiments, the vascular conduit device 100 
may be fitted with an adapter sleeve (not shown) such that the 
proximal end 7 of the tube may be connected in a fluid-tight 
manner with one or more commercially-available conduit 
devices 1020 for establishing a bypass and/or alternate path-
way between two body cavities or blood vessels. Further-
more, the vascular conduit device 100 of the present invention 
may be used to bypass and/or repair a variety of diseased 
and/or damaged blood vessels. For example, some embodi-
ments of the present invention may be used to bypass an 
abdominal aortic aneurysm (AAA) by providing two aortic 
vascular conduit devices lOOb (see FIG. 7) for example con-
nected by a section of conduit 1020 spanning the diseased 
and/or damaged portions of the abdominal aorta. 
As discussed below, the flexible flange 13 and tube 1 of 
various embodiments of the vascular conduit device 100 may 
be altered so as to be compatible with various tissue walls 
S50. For example, the vascular conduit device 100 shown in 
FIG. 7 may be suited for use in defining and maintaining an 
aperture in a large blood vessel having a curved tissue wall 
(such as the aorta). Furthermore, the vascular conduit device 
100 shown in FIG. 6 may be suited for use in defining and 
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maintaining an aperture in a body cavity having a relatively 
thick and/or muscular tissue wall (such as the cardiac muscle 
of the left ventricle). 
Therefore, as shown in FIG. 7, the flexible flange 13 may 
define, in some embodiments, a convex profile with respect to 
the proximal end 7 of the tube 1 so as to be capable of 
conforming to a curved first tissue surface S53 (such as a 
tissue surface defined by the inner wall surface of a blood 
vessel (such as the aorta)). Furthermore, in some embodi-
10 ments, the securing ring 17 may also include a flange 630 
defining a corresponding concave profile such that the secur-
ing ring 17 may be capable of operably engaging a curved 
and/or contoured second tissue surface S55 and be better 
capable of cooperating with the flexible flange 13 so as to 
15 secure the vascular conduit device 100 within the aperture 
SOO. Furthermore, as shown generally in FIG. 6, the flexible 
flange 13 may also comprise a frusto-conical assembly such 
that the insertion of the flexible flange 13 into a relatively 
narrow tissue aperture SOO may be more easily accomplished 
20 (see generally FIG. SA). Furthermore, the frusto-conical 
assembly of some flexible flange 13 embodiments of the 
present invention may also prevent and/or minimize the 
occurrence of the accidental removal of the vascular conduit 
device 100 from the second tissue surface S55 of the tissue 
25 wall S50. The relative thicknesses of the materials used to 
form the flexible flange 13 may also be varied so as to allow 
the flange 13 to be optimized based on the expected type of 
tissue wall S50 it may be used to engage. For example, a 
relatively thin and/or contoured flexible flange 13 (as shown 
30 generally in FIG. 7) may be used to secure vascular conduit 
devices 100 within more fragile and/or thin blood vessels. 
Furthermore, the relatively thick and robust frusto-conical 
flexible flange 13 (shown generally in FIG. 6) may be used to 
secure vascular conduit devices 100 within more substantial 
35 tissue walls (such as cardiac muscle). 
Tube 1 and flange 13 may be made-of any suitable biocom-
patible material. Alternatively, tube 1 and flange 13 may be 
coated with a biocompatible material. According to one 
exemplary embodiment, the tube 1 may comprise a first poly-
40 mer material having a first hardness and the flange 13 may 
comprise a second polymer material having a second hard-
ness, wherein the first hardness is greater than the second 
hardness. Thus, according to some such embodiments, the 
flange 13 may be easily deformable as it is inserted into the 
45 aperture SOO defined in the tissue wall S50, but the tube 1 may 
remain relatively rigid so as to maintain a path for fluid 
communication (see element S60, FIG. SB) between the sur-
faces S53, S55 of the tissue wall S50. 
According to some other embodiments, at least a portion of 
50 the outer surface 9 of tube 1 may be threaded. Threading 15 
may extend the entire length of tube 1, or extend over only a 
portion thereof. According to one exemplary embodiment, 
threading 15 may be absent from a length of the distal end 5 
of the tube 1 that is slightly less than the thickness of the tissue 
55 wall S50. This alternative embodiment may serve to prevent 
over-tightening of the vascular conduit device 100, which 
may, in some case lead to damage and/or rupture of portions 
of the tissue wall S50 near the aperture SOO defined therein. 
According to another embodiment, threading 15 may not 
60 extend all the way to the proximal end 7 such that the tube 1 
(and the resulting vascular conduit device 100) may be used to 
provide a conduit through tissue walls having a variety of 
thicknesses. 
External ring 17 (or securing ring 17) may be provided with 
65 an inner diameter lS and an outer diameter 19. Inner diameter 
lS may further define threads 23 to correspond to the thread-
ing 15 on the outer surface 9 of tube 1. The outer diameter 19 
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of external ring 17 may have any shape suitable to the 
designer, including circular or hexagonal. According to one 
embodiment of the invention, external ring 17 may be adapted 
to be engaged by a tightening device (not shown) for tighten-
ing external ring 17 on tube 1. As discussed above with 
respect to the tube 1, the external ring 17 may be made of any 
suitable biocompatible material. Alternatively, external ring 
17 may be coated with a biocompatible material. 
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tissue surface SSS of the heart muscle (see generally FIG. SB, 
showing the vascular conduit device 100 secured within the 
aperture SOO). 
According to the embodiment shown in FIGS. 1 and 4, 
release device 37 may include one or more hooks 39 extend-
ing from the proximal surface 41 of the external ring 17 and 
adapted to releasably engage an engagement feature 43; for 
example, a slot or bore, defined in tube 1. Alternatively, as 
shown in FIG. 5, the release device 3 7 may extend to and hook For embodiments wherein the tube defines threading 15 
and wherein the complementary external ring 17 defines 
threads 23, the tightening device may comprise a specialized 
wrench device for rotating the external ring 17 relative to the 
tube 1. Furthermore, in other embodiments (such as those 
shown generally in FIGS. 6 and 7) the tightening device may 
comprise a simple push tool capable of encircling a coring 
device S30 (see discussion below of FIG. SA) and pushing the 
external ring 17 towards the distal end5 of the tube 1 such that 
the at least one pawl member 620 of the external ring 17 may 
10 over the proximal end 7 of tube 1. 
In some additional embodiments, a portion of tube 1 may 
be threaded and the inside diameter of external ring 17 
threaded to permit further tightening of external ring 17 on 
tube 1 after deployment of the external ring 17 following 
15 removal of the release device 37. 
be engaged with the plurality of ridges 610 defined on an 
outer surface of the tube 1. According to some embodiments 20 
of the present invention, as shown generally in FIG. 11, the 
vascular conduit device 100 may be selectively secured to the 
coring device S30 (or, in some embodiments, the delivery 
device 910, discussed below) by a pin S31 and notch 101 
arrangement. For example, as showninFIG.11 a pinS31 may 25 
extend from an external surface of the coring device S30 (or 
the delivery device 910) and be operably engaged with a 
complementary notch 101 defined in the proximal end of the 
vascular conduit device 100. Thus, a clinician may use the 
coring device S30 (or the delivery device 910) to advance the 30 
vascular conduit device 100 to the aperture SOO and into an 
implanted position (see FIG. SB, for example) and subse-
quently apply counter-traction to the vascular conduit device 
100 (via the pin S31) such that the external ring 17 may be 
advanced and secured relative to the vascular conduit device 35 
100. In some embodiments, the clinician may then rotate the 
coring device S30 (and/or the delivery device 910) to release 
the pin S31 from the notch 101 and retract the coring device 
S30, leaving the vascular conduit device 100 securely 
implanted (as shown generally in FIG. SB). Furthermore, in 40 
some embodiments, the hemostatic device S20 (see FIG. SA) 
may also be used to apply counter-traction force to hold the 
tube 1 and flexible flange 13 in place within the aperture SOO 
Some embodiments of the present invention, as shown 
generally in FIG. SA, further provide a system for implanting 
a vascular conduit device 100, wherein the system comprises 
a coring device S30 for defining an aperture SOO in a tissue 
wall SSO having a first tissue surface S53 and a second tissue 
surface SSS. The various components of the system embodi-
ments of the present invention may be inserted into a patient 
(via, for example, a thoracoscopic, endovascular, and/or per-
cutaneous procedure) such that a guide catheter (not shown) 
and/or guide wire SlO (see FIG. SB) may be inserted into the 
thoracic cavity of a patient in order to gain access to diseased 
vasculature and/or the heart. Furthermore, according to some 
embodiments, the system of the present invention may be 
used to implant a vascular conduit device 100 via more inva-
sive surgical procedures that will be appreciated by one 
skilled in the art. Furthermore, as shown generally in FIG. 12, 
the vascular conduit device 100 may also be delivered and 
implanted endovascularly from the inside (and/or from a first 
tissue surface S53) of the ventricle and/or aorta. 
As shown in FIG. SA, the coring device S30 may define a 
lumen adapted to be capable of receiving a guide wire Sl 0 for 
directing the coring device S30 to the second tissue surface 
SSS. Furthermore, the system of the present invention may 
also comprise a conduit device 100 (such as the vascular 
conduit device discussed above) for lining the aperture SOO 
defined in the tissue wall SSO and maintaining fluid commu-
nication between the first S53 and second tissue SSS surfaces 
of the tissue wall SSO. The conduit device 100 may be adapted 
to be capable of being advanced over the guide wire SlO and as the external ring 17 is engaged with respect to the second 
tissue surface SSS from a proximal position. 
According to the embodiment shown in FI GS. 3 and 4, tube 
45 coring device S30. As described above with respect to FIGS. 
1-5, the vascular conduit device 100 may comprise: a tube 1 
having proximal 7 and distal 5 ends, and inside and outside 
surfaces; a flexible flange 13 disposed at or near the distal end 
1 of the vascular conduit device 100 may also be provided 
with an external ring 17 that is biased toward flange 13 by a 
biasing device 27 (such as a spring device), having proximal 
end 29 and distal end 31. The biasing device 27 may be 50 
configured so as to tend to force external ring 17 into contact 
with flange 13. As shown in FIGS. 4-6, the biasing device 27 
may be a spring in compression. As one of ordinary skill in the 
5; and a securing ring 17 (or external ring 17) adapted to fit 
over the tube 1 and adapted to be capable of operably engag-
ing the second tissue surface SSS and cooperating with the 
flexible flange 13 so as to secure the conduit device 100 within 
a tissue aperture SOO. 
According to various embodiments of the system of the 
present invention, the coring device S30 may comprise at 
least one of: a pulsed laser scalpel; a continuous wave laser 
scalpel; a mechanical coring device (such as, for example, a 
rotoblator catheter or other mechanical and/or catheter-based 
mechanical cutting device); an ultrasonic coring device (such 
art will appreciate, any biasing device may be used, including 
one or more flexible bands or rods. Furthermore, tube 1 may 55 
be provided with and/or define an engagement feature 33, 
such as a ring, slot or bore, to engage the proximal end 29 of 
the biasing device 27. Likewise, external ring 17 may be 
provided with an engagement feature (not shown) adapted to 
receive the distal end 31 of the biasing device 27. 60 as high-frequency focused ultra-sound); and combinations 
thereof. For example, in one exemplary embodiment, the 
coring device S30 may comprise a pulsed excimer laser 
device having a light pulse duration that is less than the tissue 
According to some embodiments, release device 37 may 
also be provided to releasably hold external ring 17 and 
biasing device 27 in pre-deployment configuration, with bias-
ing device 27 in compression, until such a time as the flange 
13 has been placed in the interior of a cavity defined by the 65 
tissue wall SSO (such as the interior of the ventricle) and the 
external ring 17 is ready to be deployed against the outer 
wall's SSO time of thermal diffusion (defining how quickly 
the laser's imparted heat spreads to adjacent tissue) so as to 
provide a relatively "cool" cutting method (i.e. less than about 
50 degrees C.). Furthermore, the pulsed laser may be pro-
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vided with a relatively shallow cutting depth (i.e. less than 
about 50 µm) such that the coring device S30 may be precisely 
controlled. The use of a pulsed laser scalpel as the coring 
device S30 may thus result in minimal damage to tissue 
adjacent the targeted aperture SOO area, which may be espe-
cially advantageous in embodiments wherein the system is 
used to implant a vascular conduit device 100 in the ventricu-
lar apex, as the cardiac tissue of the left ventricle contains 
tissues that are vital for maintaining the electrical pacing of 
the heart. 
Some system embodiments of the present invention (as 
shown generally in FIG. SA) may further comprise a hemo-
static device S20 for selectively deploying so as to tempo-
rarily occlude the aperture SOO. As one skilled in the art will 
appreciate, the hemostatic device S20 may be adapted to be 
capable of being advanced over the guide wire Sl 0 within the 
lumen of the coring device S30. Furthermore, according to 
some embodiments, the hemostatic device S20 may be deliv-
ered via a delivery catheter defining a lumen for receiving the 
guide wire Sl 0 and having a sufficiently small outer diameter 
to be guided within the lumen defined by the coring device 
S30. According to various embodiments of the present inven-
tion, the hemostatic device S30 may comprise at least one of: 
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vascular conduit device 100 to a secured position (see FIG. 
SA, for example) relative to the aperture SOO defined in the 
tissue wall S50. The delivery device 910 may be operably 
engaged with an outer surface of the coring device S30 and 
may comprise two or more retractor arms 912 that may be 
opened as the vascular conduit device 100 is pushed out from 
the delivery device SlO by applying an opening force to a 
plunger 915. Thus, as shown in FIG. 9B, the delivery device 
910 may be configured to simultaneously dilate the aperture 
10 SOO (using the retractor arms 912) and deliver the vascular 
conduit device 100. As shown in FIG. 9B the flexible flange 
13 of the vascular conduit device 100 may urge the retractor 
arms 912 to an open position as the plunger 915 pushes the 
vascular conduit device 100 outward and into the aperture 
15 SOO. The retractor arms 912, when deployed as shown in FIG. 
9B may also serve to provide "counter-traction" such that the 
clinician may apply a distally-acting force on the plunger 915, 
a clinician may deploy the securing ring 17 relative to the tube 
1 of the vascular conduit device 100 in order to secure the 
20 vascular conduit device 100 within the aperture SOO (as 
shown in FIG. SB, for example). 
an "umbrella" occlusion device; a dilation balloon; and/or 
combinations thereof. According to some embodiments, the 25 
hemostatic device S20 (as shown in FIG. SA) may be used to 
maintain "traction" for the advance of the coring device S30 
(which, in pulsed excimer laser embodiments, may comprise 
As described above (see FIG. SA, for example) the hemo-
static device S20 may also be deployed in order to provide 
additional "counter-traction" such that the distal end of the 
vascular conduit device 100 (once implanted in the aperture 
SOO) may contact the expanded hemostatic device S20. Thus, 
by applying a distally-acting force on the plunger 915, a 
clinician may deploy the securing ring 17 relative to the tube 
1 of the vascular conduit device 100 in order to secure the a circular array S35 of lasers that must be advanced into the 
tissue wall S50 in order to core the wall and define an aperture 30 
SOO therein). Thus, in some embodiments, a clinician may 
deploy the hemostatic device S20 proximal to the first tissue 
surface S53 of the tissue wall S50 and exert a force (using the 
deployed hemostatic device) against the first tissue surface 
S53 such thatthe laser array S35 of the coring device S30 may 35 
be advanced to define the aperture SOO in the tissue wall S50. 
The exertion of such "traction" forces using the hemostatic 
device S20 may be useful in instances wherein the tissue wall 
S50 is in motion (such as is the case with the cardiac muscle 
defining the walls of the left ventricle). Thus, embodiments of 40 
the present invention may be successfully employed in "off-
pump" procedures wherein the heart is left beating during the 
course of the procedure for implanting the vascular conduit 
device 100. 
vascular conduit device 100 within the aperture SOO (as 
shown in FIG. SB, for example). 
According to one exemplary embodiment, the system of 
the present invention (shown generally in FIGS. SB and 10) 
may be used to implant vascular conduit devices lOOa, lOOb 
to serve as the terminal points for an apico-aortic conduit. 
According to such embodiments, a thoracoscopic procedure 
may be used to insert a needle through the apex and into the 
left ventricle S50a. A guide wire SlO may then inserted into 
the opening and, following dilation of the opening (using a 
dilation device, for example), an hemostatic device S20 may 
be threaded over the wire SlO and into the left ventricle and 
deployed proximal to an first tissue surface S53 thereof. The 
hemostatic device S20 may comprise, for example, known 
occlusion devices such as an occlusion balloon, the Guidant 
Following the coring process, the vascular conduit device 
100 (as described in its various embodiments above) may be 
advanced along the outer surface of the coring device S30 and 
into position within the aperture (as shown generally in FIG. 
SB) so as to define a pathway for fluid flow S60 through the 
tissue wall S50. According to some embodiments, a dilator 
device (not shown) may be introduced (over the guide wire 
Sl 0, for example) for dilating the initial aperture SOO defined 
45 Heartstring™, or the Baladi inverter, disclosed in U.S. Patent 
Nos. 5,944,730and 6,409,739. As described above, and as 
shown generally in FIG. 12, the vascular conduit devices 
lOOa, lOOb may also be implanted endovascularly (i.e. from 
the inside of the left ventricle and/or the aorta) by introducing 
by the coring device S30. The dilator device may also be used 
to advance the vascular conduit device 100 into its final 
implanted position (see FIG. SB) by at least partially expand-
ing the dilator device within the inner surface 11 of the tube 1 
so as to carry the vascular conduit device 100 with the par-
tially-expanded portion of the dilator device. The dilator 
device may comprise, in various embodiments, a dilation 
balloon, a multi-arm endoscopic and/or thoracoscopic retrac-
tor device, and/or other types of dilator devices that will be 
appreciated by one skilled in the art. 
50 the system embodiments of the present invention through the 
vasculature via guidewire and/or guiding catheter. For 
example, the aortic conduit lOOb may be introduced via the 
system embodiments of the present invention (including a 
guiding catheter) inserted in the femoral artery. In addition, 
55 the ventricular conduit lOOa may be introduced via the sys-
tems of the present invention (including a guiding catheter) 
inserted into the femoral vein, across the atrial septum, 
through the mitral valve and out the ventricular free wall. 
A ventricular coring device S30 may then be threaded 
60 in-line over the hemostatic device S20 and a core ofventricu-
For example, as shown generally in FIGS. 9A and 9B, 
some embodiments of the present invention may comprise a 
dilator device that may serve as a delivery device 910 for 65 
dilating the aperture SOO formed by the coring device S30 and 
for percutaneously and/or thoracoscopically delivering the 
lar muscle is removed from the tissue wall S50 of the apex in 
order to form an aperture SOO. In addition to known coring 
techniques, an annular contact laser (and in some embodi-
ments a "cool" cutting pulsed excimer laser, having elements 
arranged in a circular array S35) may be used to vaporize the 
tissue along the perimeter of the core. The cored tissue may 
then be removed according to known methods. According to 
US 9, 138,228 B2 
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a further alternative embodiment, a contact laser may be used 
to vaporize the entire area of the core, eliminating the need to 
remove cored tissue. In yet another embodiment, a mechani-
cal coring device (such as a catheter-based rotoblator device) 
or an ultrasonic coring device, may be used to form the 
aperture 800. No matter the method of coring, once coring has 
been-completed, the coring device 830 may be removed 
while the occlusion device maintains hemostasis, and the 
vascular conduit device 100 of the present invention may be 
mounted on a dilator and-introduced over the guide wire 810 10 
and hemostatic device 820. As the vascular conduit device 
100 is introduced into the aperture 800 in the apex, the flexible 
flange 13 may deform and/or retract. As the vascular conduit 
device 100 enters the-left ventricle, it may displace the hemo-
static device 820 to allow the flexible flange 13 to resume its 15 
normal shape. As discussed above the vascular conduit device 
100 may then be drawn tight against the first tissue surface 
853 of the wall 850 of the left ventricle. According to a first 
embodiment, external ring 17 is threaded onto the tube 1 and 
tightened until it is snug against the second tissue surface 855 20 
of the ventricular apex. 
According to it second embodiment, once the flexible 
flange 13 has been introduced into the ventricle and pulled 
back to engage the first tissue surface 853, release-device 37 
is released, allowing biasing device 27 to force the external 25 
ring 17 against the second tissue surface 855 of the ventricular 
apex. According to a further aspect of this embodiment of the 
invention, threads on the inside diameter of external ring 17 
may be made to engage threads on the outer surface of the 
tube 1 to further secure external ring 17 against the tissue wall 30 
850 of the ventricular apex. 
Once the vascular conduit device 100 is firmly in place (see 
generally FIG. SB), the occlusion device 820 may be retracted 
and withdrawn. The vascular conduit device 100 may then be 
clamped shut and/or capped while its free end (defined by the 35 
proximal end 7 of the tube 1) is connected to a valved conduit 
and/or graft which may terminate at a complementary vascu-
lar conduit device 100 implanted in the aorta (see FIG. 7 
showing an exemplary embodiment of a vascular conduit 
device 100 suited for implantation in the tissue wall 850 of the 40 
aorta). 
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second tissue surfaces of the tissue wall, the sutureless 
conduit device adapted to be separably positioned over 
and coaxial with the coring device and to be advanced 
over the coring device and into the aperture, the suture-
less conduit device comprising a tube having proximal 
and distal ends, and inside and outside surfaces, the 
inside surface of the tube adapted to slidably contact an 
outer surface of the coring device when the sutureless 
conduit device is positioned over the coring device; and 
a delivery device for selectively deploying the sutureless 
conduit device into the aperture, the delivery device 
comprising a plurality of retractor arms adapted to 
engage the tissue wall and to provide counter-traction 
for advancing the sutureless conduit device into the 
aperture. 
2. The system according to claim 1, wherein the coring 
device is selected from the group consisting of: 
a pulsed laser scalpel; 
a continuous wave laser scalpel; 
a mechanical coring device; 
an ultrasonic coring device; and 
combinations thereof. 
3. The system according to claim 1, wherein the articulat-
ing device comprises an umbrella occlusion device. 
4. The system according to claim 1, wherein the sutureless 
conduit device is further adapted to implant a ventricular 
assist device in the tissue wall. 
5. The system according to claim 1, wherein the sutureless 
conduit device further comprises at least one flexible flange 
disposed at or near the distal end of the tube, the flexible 
flange having a larger outer diameter than the tube and 
adapted to operably engage the first tissue surface. 
6. The system according to claim 5, wherein the flexible 
flange has a frusto-conical shape. 
7. The system according to claim 5, wherein the flexible 
flange is adapted to deform sufficiently to allow the distal end 
of the tube and the flange to be inserted through the aperture 
defined in the tissue wall, the aperture having a diameter equal 
to or less than the diameter of the tube. 
Many modifications and other embodiments of the inven-
tions set forth herein will come to mind to one skilled in the art 
to which these inventions pertain having the benefit of the 
teachings presented in the foregoing descriptions and the 
associated drawings. Therefore, it is to be understood that the 
inventions are not to be limited to the specific embodiments 
disclosed and that modifications and other embodiments are 
intended to be included within the scope of the appended 
claims. Although specific terms are employed herein, they are 
used in a generic and descriptive sense only and not for 
purposes of limitation. 
8. The system according to claim 7, wherein the flexible 
flange has sufficient shape memory that once deformed to 
allow insertion of the distal end of the tube and the flange 
45 through the aperture, the flange will return to a larger original 
shape. 
That which is claimed: 
1. A system for implanting a vascular conduit device, the 
system comprising: 
a coring device for defining an aperture in a tissue wall 
having a first tissue surface and a second tissue surface, 
the coring device defining a lumen adapted to receive a 
guide for directing the coring device to the second tissue 
surface; 
an articulating device for selectively deploying through the 
tissue wall and proximate the first tissue surface, the 
articulating device adapted to provide counter-traction 
for advancing the coring device into the tissue wall and 
to selectively occlude the aperture; 
a sutureless conduit device for lining the aperture and 
maintaining fluid communication between the first and 
9. The system according to claim 5, wherein the flexible 
flange extends about an entire circumference of the tube. 
10. The system according to claim 1, wherein the sutureless 
50 conduit device is further adapted forthe passage of medical or 
surgical instruments during an intervention through the tissue 
wall. 
11. The system according to claim 1, further comprising a 
55 
guiding wire or a guiding catheter for directing the coring 
device and the sutureless conduit device to the tissue wall via 
an endovascular pathway. 
12. The system according to claim 1, wherein a proximal 
end of the sutureless conduit device is operably engaged with 
60 the coring device. 
13. The system according to claim 1, wherein the delivery 
device further comprises a plunger adapted to be slidably 
disposed with respect to the coring device and to advance the 
sutureless conduit device over the coring device and into the 
65 aperture, and wherein the retractor arms are adapted to 
engage the tissue wall while the plunger advances the conduit 
device over the coring device and into the aperture. 
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14. The system according to claim 13, wherein the retractor 
arms are adapted to dilate the aperture while the plunger 
advances the conduit device over the coring device and into 
the aperture. 
15. The system according to claim 1, further comprising a 
valve adapted to control fluid flow through the sutureless 
conduit device. 
16. The system according to claim 15, wherein the valve is 
adapted for the passage of medical or surgical instruments. 
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operably engage the second tissue surface so as to 
secure the sutureless conduit device in the aperture; 
and 
a delivery device for selectively deploying the sutureless 
conduit device into the aperture, the delivery device 
comprising: 
a plurality of retractor arms adapted to engage the tissue 
wall and to provide counter-traction for advancing the 
sutureless conduit device into the aperture; and 
17. The system according to claim 1, wherein the articu- 10 
lating device is adapted to be advanced over the guide and 
within the lumen of the coring device. 
a plunger adapted to advance the sutureless conduit 
device over the coring device and into the aperture. 
25. The system according to claim 24, wherein the suture-
less conduit device is further adapted to implant a ventricular 
15 assist device in the tissue wall. 
18. The system according to claim 1, wherein the articu-
lating device is adapted to be advanced over the guide and 
within the lumen of the sutureless conduit device. 
19. The system according to claim 1, wherein the retractor 
arms are adapted to dilate the aperture. 
20. The system according to claim 1, wherein the retractor 
arms are flexible. 
21. The system according to claim 1, wherein the retractor 20 
arms are adapted to move from a closed position to an open 
position as the sutureless conduit device is advanced over the 
coring device and into the aperture. 
22. The system according to claim 1, wherein the sutureless 
conduit device is adapted to move the retractor arms from a 25 
closed position to an open position as the sutureless conduit 
device is advanced over the coring device and into the aper-
ture. 
23. The system according to claim 1, wherein the retractor 
arms extend over the sutureless conduit device. 
24. A system for implanting a vascular conduit device, the 
system comprising: 
30 
a coring device for defining an aperture in or near a ven-
tricular apex of a heart tissue wall having an inner first 
tissue surface and an outer second tissue surface, the 35 
coring device defining a lumen adapted to receive a 
guide for directing the coring device to the second tissue 
surface, the coring device adapted to remove and capture 
a core of tissue from the heart tissue wall to define the 
aperture; 
an articulating device for selectively deploying through the 
heart tissue wall and proximate the first tissue surface, 
the articulating device adapted to provide a hemostatic 
surface about the first tissue surface when the articulat-
40 
ing device is in an expanded configuration, to provide 45 
counter-traction for advancing the coring device into the 
heart tissue wall and to selectively occlude the aperture; 
a sutureless conduit device for lining the aperture and 
maintaining fluid communication between the first and 
second tissue surfaces of the heart tissue wall, the suture- 50 
less conduit device adapted to be separably positioned 
over and coaxial with the coring device and to be 
advanced over the coring device and into the aperture, 
the sutureless conduit device comprising: 
a tube having proximal and distal ends, and inside and 55 
outside surfaces, the inside surface of the tube adapted 
to slidably contact an outer surface of the coring 
device when the sutureless conduit device is posi-
tioned over the coring device; 
a flexible flange disposed at or near the distal end of the 60 
tube, the flexible flange having a frusto-conical shape 
expanding from a distal end to a proximal end thereof, 
the flexible flange adapted to deform sufficiently to be 
inserted through the aperture and to operably engage 
the first tissue surface; and 65 
a securing ring adapted to selectively engage the outer 
surface of the tube and to advance over the tube to 
26. The system according to claim 24, wherein the retractor 
arms are adapted to engage the tissue wall while the plunger 
advances the sutureless conduit device over the coring device 
and into the aperture. 
27. The system according to claim 24, wherein the articu-
lating device comprises an umbrella occlusion device. 
28. The system according to claim 24, further comprising a 
valve adapted to control fluid flow through the sutureless 
conduit device. 
29. The system according to claim 28, wherein the valve is 
adapted for the passage of medical or surgical instruments. 
30. A system for implanting a vascular conduit device, the 
system comprising: 
a coring device for defining an aperture in a tissue wall 
having a first tissue surface and a second tissue surface, 
the coring device defining a lumen adapted to receive a 
guide for directing the coring device to the second tissue 
surface, the coring device adapted to remove and capture 
a core of tissue from the tissue wall to define the aper-
ture; 
a sutureless conduit device for lining the aperture and 
maintaining fluid communication between the first and 
second tissue surfaces of the tissue wall, the sutureless 
conduit device adapted to be separably positioned over 
and coaxial with the coring device and to be advanced 
over the coring device and into the aperture, the suture-
less conduit device comprising a tube having proximal 
and distal ends, and inside and outside surfaces, the 
inside surface of the tube adapted to slidably contact an 
outer surface of the coring device when the sutureless 
conduit device is positioned over the coring device; and 
a delivery device for selectively deploying the sutureless 
conduit device into the aperture , the delivery device 
comprising: 
a plurality of retractor arms adapted to engage the tissue 
wall and to provide counter-traction for advancing the 
sutureless conduit device into the aperture; and 
a plunger adapted to advance the sutureless conduit 
device over the coring device and into the aperture. 
31. A system for implanting a vascular conduit device, the 
system comprising: 
a coring device for defining an aperture in or near a ven-
tricular apex of a heart tissue wall having a first tissue 
surface and a second tissue surface, the coring device 
adapted to be advanced over a guidewire and to remove 
a core of tissue from the heart tissue wall to define the 
aperture; 
a sutureless conduit device for lining the aperture and 
maintaining fluid communication between the first and 
second tissue surfaces of the heart tissue wall, the suture-
less conduit device adapted to be advanced over the 
coring device and into the aperture; 
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a valve adapted to control blood flow through the sutureless 
conduit device; and 
a delivery device for selectively deploying the sutureless 
conduit device into the aperture, the delivery device 
comprising a plurality of retractor arms adapted to 5 
engage the tissue wall and to provide counter-traction 
for advancing the sutureless conduit device into the 
aperture. 
* * * * * 
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